Currently, there are 16.82M common shares owned by the public and among those 15.59M shares have been available to trade.
The company’s stock has a 5-day price change of -26.52% and -44.53% over the past three months. BMRA shares are trading -57.40% year to date (YTD), with the 12-month market performance down to -59.04% lower. It has a 12-month low price of $0.66 and touched a high of $2.13 over the same period. BMRA has an average intraday trading volume of 180.65K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -31.54%, -44.39%, and -48.33% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Biomerica Inc. (NASDAQ: BMRA) shares accounts for 22.27% of the company’s 16.82M shares outstanding.
It has a market capitalization of $8.96M and a beta (3y monthly) value of -0.95. The earnings-per-share (ttm) stands at -$0.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.38% over the week and 10.73% over the month.
Analysts forecast that Biomerica Inc. (BMRA) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2025. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$ a year ago.
Looking at the support for the BMRA, a number of firms have released research notes about the stock. Colliers Securities stated their Buy rating for the stock in a research note on November 10, 2020, with the firm’s price target at $13. B. Riley FBR Inc. coverage for the Biomerica Inc. (BMRA) stock in a research note released on January 04, 2018 offered a Buy rating with a price target of $7.50.
